Cardio Diagnostics Holdings, Inc. announced a significant move to transform global cardiovascular health, by entering into a Supply and Distribution Agreement with Aimil Ltd. Aimil, a company at the forefront of the instrumentation industry in India since32 with 14 sales and services offices across India, is a leader in introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India. Cardio Diagnostics and Aimil intend to further expand the Supply and Distribution Agreement after a successful phase one, to ensure that customers in India have consistent and reliable access to Cardio Diagnostics' diagnostic test. With Cardio Diagnostics' PrecisionCHD test, there is a significant opportunity to reduce the burden of CHD across India.

Unlike current tests to diagnose CHD such as a stress test and CCTA, PrecisionCHD does not require costly infrastructure nor exposing a patient to radiation or kidney-damaging contrast dye. PrecisionCHD only requires a simple blood draw from the patient, allowing for this test to be deployed at scale in both urban and rural settings.